Literature DB >> 7525961

L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase.

W M Moore1, R K Webber, G M Jerome, F S Tjoeng, T P Misko, M G Currie.   

Abstract

L-N6-(1-Iminoethyl)lysine (L-NIL) has been synthesized and is shown to be both a potent and selective inhibitor of mouse inducible nitric oxide synthase (miNOS). L-NIL has an IC50 of 3.3 microM for miNOS compared to an IC50 of 92 microM for rat brain constitutive NOS indicating that L-NIL is 28-fold more selective for inducible NOS. L-N5-(1-Iminoethyl)ornithine (L-NIO), which differs from L-NIL by having one less methylene group, has very similar potency for inducible NOS, but lacks selectivity. DL-N7-(1-Iminoethyl)homolysine was also synthesized and found to be substantially less potent than L-NIL or L-NIO, with intermediate selectivity for inducible NOS. These data suggest that L-NIL may be useful as a selective inhibitor of inducible NOS for determining the role of this enzyme in disease models.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525961     DOI: 10.1021/jm00049a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  83 in total

1.  Nitric oxide synthase is induced in sporulation of Physarum polycephalum.

Authors:  G Golderer; E R Werner; S Leitner; P Gröbner; G Werner-Felmayer
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

3.  Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels.

Authors:  Janet R Manning; Gregory Carpenter; Darius R Porter; Stacey L House; Daniel A Pietras; Thomas Doetschman; Jo el J Schultz
Journal:  Growth Factors       Date:  2012-02-06       Impact factor: 2.511

4.  Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis.

Authors:  L L Shears; N Kawaharada; E Tzeng; T R Billiar; S C Watkins; I Kovesdi; A Lizonova; S M Pham
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

5.  2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo.

Authors:  W S Faraci; A A Nagel; K A Verdries; L A Vincent; H Xu; L E Nichols; J M Labasi; E D Salter; E R Pettipher
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

6.  Reduction in embryonic malformations and alleviation of endoplasmic reticulum stress by nitric oxide synthase inhibition in diabetic embryopathy.

Authors:  Zhiyong Zhao; Richard L Eckert; E Albert Reece
Journal:  Reprod Sci       Date:  2012-04-24       Impact factor: 3.060

7.  Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.

Authors:  Yun Wang; Arthur F Monzingo; Shougang Hu; Tera H Schaller; Jon D Robertus; Walter Fast
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

8.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

9.  Brain-derived neurotrophic factor (BDNF) induces sustained intracellular Ca2+ elevation through the up-regulation of surface transient receptor potential 3 (TRPC3) channels in rodent microglia.

Authors:  Yoshito Mizoguchi; Takahiro A Kato; Yoshihiro Seki; Masahiro Ohgidani; Noriaki Sagata; Hideki Horikawa; Yusuke Yamauchi; Mina Sato-Kasai; Kohei Hayakawa; Ryuji Inoue; Shigenobu Kanba; Akira Monji
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

10.  Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors.

Authors:  D Salvemini; P T Manning; B S Zweifel; K Seibert; J Connor; M G Currie; P Needleman; J L Masferrer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.